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Caspase 3 Promotes Surviving Melanoma Tumor Cell
Growth after Cytotoxic Therapy
Anne L. Donato1,2,4, Qian Huang1,3,4, Xinjian Liu1, Fang Li1, Mary A. Zimmerman1 and Chuan-Yuan Li1
Metastatic melanoma often relapses despite cytotoxic treatment, and hence the understanding of melanoma
tumor repopulation is crucial for improving our current therapies. In this study, we aim to define the role of
caspase 3 in melanoma tumor growth after cytotoxic therapy. We examined a paradigm-changing hypothesis that
dying melanoma cells undergoing apoptosis during cytotoxic treatment activate paracrine signaling events that
promote the growth of surviving tumor cells. We propose that caspase 3 has a key role in the initiation of the
release of signals from dying cells to stimulate melanoma tumor growth. We created a model for tumor cell
repopulation in which a small number of luciferase-labeled, untreated melanoma cells are seeded onto a layer of
a larger number of unlabeled, lethally treated melanoma cells. We found that dying melanoma cells significantly
stimulate the growth of living melanoma cells in vitro and in vivo. Furthermore, we observed that caspase 3 gene
knockdown attenuated the growth-stimulating effect of irradiated, dying cells on living melanoma cell growth.
Finally, we showed that caspase 3–mediated dying melanoma cell stimulation of living cell growth involves
secreted prostaglandin E2 (PGE2). Our study therefore suggests a counterintuitive strategy to inhibit caspase 3 for
therapeutic gain in melanoma treatment.
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INTRODUCTION
Melanoma is a highly aggressive cancer whose incidence is
increasing more substantially than that of any other type of
cancer (Siegel et al., 2012). Metastatic melanoma portends a
poor prognosis (Balch et al., 2009), thereby suggesting that our
current therapies are often ineffective in eliminating all of the
melanoma tumor cells.
In order to investigate melanoma recurrence after cytotoxic
therapy, one must explore the fundamental mechanism of tumor
repopulation. A relevant concept is the idea of ‘‘accelerated
repopulation’’ after radiotherapy (Tubiana, 1988; Trott, 1990).
Currently, the mechanisms behind this process of melanoma
tumor repopulation after cytotoxic therapy are poorly under-
stood. Inflammation and angiogenesis have been identified as
having a role in ‘‘accelerated repopulation’’ (Martin et al., 2003;
Reuter et al., 2010). However, because inflammation and angio-
genesis are more likely to be secondary events, the initiating event
that drives melanoma tumor repopulation remains unexplored.
Recently, our laboratory discovered the ‘‘Phoenix Rising’’
pathway that may define a possible cell death–mediated
mechanism that drives melanoma tumor repopulation (Huang
et al., 2011). We have identified caspase 3, a key molecule
in the ‘‘executioner phase’’ of apoptosis, as having a key role
in the proliferation of surrounding cells (Li et al., 2010b;
Huang et al., 2011). Caspase 3 activates calcium-independent
phospholipase A2 (Zhao et al., 2006). Activated calcium-
independent phospholipase A2 increases the synthesis and
release of arachidonic acid and lysophosphocholine from
apoptotic cells (Akiba and Sato, 2004). Arachidonic acid
is a known precursor to prostaglandin E2 (PGE2). PGE2 is
involved in stem cell proliferation, tissue regeneration,
and wound healing (Surh et al., 2012). Furthermore, PGE2
increases tumor growth in many types of cancers such as
colon (Castellone et al., 2005), prostate (Vo et al., 2013),
breast (Zhao et al., 1996), and lung (Singh and Katiyar, 2013)
cancers.
In this study, we have attempted to create a model for
melanoma repopulation by combining a small number of
untreated, luciferase-labeled melanoma cells with a larger
number of lethally treated, unlabeled melanoma cells and
then measuring the luciferase activity over time. This simulates
the in vivo treatment of a tumor in which the majority of cells
are killed by the cytotoxic treatment, whereas only a few cells
survive and go on to repopulate the tumor in the case of a
relapse. We implemented this model in vitro using standard
and transwell cell culture plates and also in mice. We used
this model to study the role of caspase 3 in melanoma tumor
repopulation after cytotoxic treatments.
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RESULTS
Cytotoxic treatments activate caspase 3 in melanoma cells
To observe caspase 3 activation in dying melanoma cells, we
treated A375 melanoma cells with radiation or vemurafenib
and examined caspase 3 activation using western blot analysis
and an activated caspase 3 reporter. Western blots for
activated caspase 3 showed an increase in protein expression
for 1, 2, and 3 days after irradiation with 10 Gy or treatment
with vemurafenib 20mM in A375 cells (Figure 1a). We created
a caspase 3 reporter gene containing a polyubiquinated
region, a firefly luciferase gene fused with a green fluorescent
protein (GFP) gene (GFP-Luc), and a caspase 3 cleavage site
(Figure 1b). In normal melanoma cells, the polyubiquitin tag
remains attached to the reporter construct, and hence the
fusion GFP-Luc reporter protein will be rapidly degraded by
the proteasome. When caspase 3 is activated in dying
melanoma cells, activated caspase 3 acts as a protease and
cleaves off the polyubiqutin domain so that the GFP-Luc
reporter becomes stabilized in cells and can be measured
using bioluminescence. Our results illustrate a significant
increase in luciferase activity and GFP expression in both
the irradiated (440-fold increase) and vemurafenib-treated
(46-fold increase) A375 caspase 3 reporter cells (Figure 1c
and d). As these results indicated that cytotoxic melanoma
treatment activates caspase 3, we proceeded to investigate the
evidence for a role for caspase 3 in cell death stimulation of
melanoma cell growth.
Dying melanoma cells promote the growth of living melanoma
cells in vitro and in vivo
To validate a role for cell death and caspase 3 in melanoma
tumor repopulation, we tested the ability of dying melanoma
cells to induce the growth of living melanoma cells in vitro
and in vivo. Our in vitro model of melanoma tumor repopula-
tion included a small number (200–500) of untreated, lucifer-
ase reporter melanoma (A375Fluc or A2508Fluc) cells seeded
onto a large number (1 105) of A375 or A2508 melanoma
cells lethally treated with cytotoxic therapy. In order to validate
our model, we confirmed that luminescence was linearly
correlated with A375Fluc and A2508Fluc cell numbers
(Supplementary Figures S1 and S2 online). Our results show
that lethally irradiated (10 Gy) or vemurafenib-treated A375
and A2508 melanoma cells significantly (Po0.05, analysis of
variance) stimulate the growth of living reporter cells compared
with no feeder and untreated controls (Figure 2a–d). Remark-
ably, when compared with no feeder controls, after 2 weeks
there was an over 110-fold difference in reporter cell luciferase
activity when cocultured with 10 Gy-irradiated A375 cells
(Figure 2a) and over 137-fold difference in reporter cell
luciferase activity when cocultured with 10 Gy-irradiated
A2508 cells (Figure 2b). In addition, the growth-stimulating
effect of dying melanoma cells on living melanoma cells was
also observed in transwell plates, thereby providing definitive
evidence that a secreted factor is involved in this process
(Figure 2e and f). Furthermore, we have evidence that dying
A375 could stimulate the growth of untreated A2508Fluc cells
and vice versa (Supplementary Figure S3 online). Therefore,
the cytotoxic treatment of melanoma cells in vitro greatly
enhances the growth of living melanoma tumors cells and this
effect involves secreted factors from the dying cells.
Next, we studied whether or not cell death–mediated
melanoma tumor repopulation occurred in vivo. A375 cells
were treated with 10 Gy radiation or vemurafenib 20mM for
3 days. A large number of the lethally treated A375 cells
(2 105) were injected with a small number (1104) of
untreated, luciferase-labeled A375Fluc cells and biolumines-
cence was monitored over 2 weeks as a measure of A375Fluc
growth. Consistent with our in vitro observations, we found
that dying A375 cells treated with either radiation or vemur-
afenib significantly (at 13 days, a 62-fold increase for radia-
tion, Po0.05; Figure 3a and b and a 114-fold increase for
vemurafenib, Po0.05; Figure 3c and d) stimulated the growth
of the small number of living A375Fluc cells compared with
the untreated A375 feeder controls. Thus, our in vitro and
in vivo results establish the importance of dying cells for
melanoma tumor repopulation with two possible melanoma
cytotoxic treatments.
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Figure 1. Cytotoxic treatment increases activated caspase 3 levels in A375
melanoma cells. (a) Western blots for cleaved caspase 3 protein expression
in A375 cells treated with10 Gy radiation or vemurafenib (Vem) 20mM.
(b) A schematic drawing of the activated caspase 3 reporter illustrating that
luciferase (Luc) and green fluorescent protein (GFP) expression can be
quantified as a measure of activated caspase 3 activity. (c) Graph of luciferase
activity per cell versus time and pictures of GFP expression on day 5 in
irradiated A375 caspase 3 reporter melanoma cells. (d) Graph of luciferase
activity per cell versus time and pictures of GFP expression on day 5 in
vemurafenib-treated A375 caspase 3 reporter melanoma cells. Error bars are
mean±SEM, n¼3; *Po0.05, t-test.
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Caspase 3 inhibition attenuates the growth-stimulating effect of
dying melanoma cells on living melanoma cells in vitro
On the basis of our previous studies of caspase 3 in breast
cancer cells (Huang et al., 2011), we postulated that caspase 3
has a pivotal role in the pathway of dying melanoma cell
promotion of living melanoma cell growth. To attenuate
caspase 3 activities, we created two A375 melanoma cell
lines expressing two different caspase 3 short hairpin RNAs
(shRNAs; Figure 4a and b) and two melanoma cell lines (A375
and A2508) constitutively expressing a dominant-negative
caspase 3 gene (Figure 4c and d). Caspase 3 knockdown
was confirmed in our caspase 3 shRNA A375 melanoma cell
lines (Figure 4a). We showed that in both caspase 3 shRNA–
and dominant-negative caspase 3–expressing A375 cells,
apoptosis (as measured by TUNEL assay) was significantly
reduced (Supplementary Figure S4 online). In addition, we
used two genetically identical mouse embryonic fibroblast
(MEF) cell lines that are wild type or genetically deficient of
the Casp3 gene (Kuida et al., 1996; Lakhani et al., 2006)
(Figure 4e and f). When we carried out the repopulation
assay, we found that each of the aforementioned methods
of caspase 3 inhibition in feeder cells significantly decreased
the growth-stimulating effect of dying cells on living mela-
noma cells (Figure 4b–f). In an experiment comparing the two
A375 caspase 3 shRNA cell lines (15044 and 15045 seen in
Figure 4b) with a scramble cell line control, reporter cells
seeded onto irradiated caspase 3 shRNA cell lines grew
B60% that of cells seeded onto irradiated scramble cells after
9 days (Po0.05; Figure 4b). In addition, the growth of living
melanoma cells seeded onto a layer of irradiated caspase 3
knockout MEF cells was 22% that of cells seeded onto a layer
of irradiated wild-type MEF cells after 9 days (Po0.05;
Figure 4e). These results further suggest that irradiated stromal
cells may also promote melanoma cell repopulation.
Therefore, by using three different methodologies for attenu-
ating caspase 3 activities, we have obtained data that strongly
support a role for caspase 3 in melanoma tumor repopulation
during cytotoxic therapy.
Caspase 3–mediated dying cell stimulation of living melanoma
tumor cell growth occurs through a mechanism involving
secreted PGE2
Given that we previously identified PGE2 as the downstream
secreted factor from dying cell–stimulated living cell growth in
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Figure 2. Dying melanoma cells promote the growth of living melanoma reporter cells in vitro. A small number of living melanoma luciferase reporter cells
were seeded onto a larger number of lethally treated, unlabeled melanoma cells. (a, b) Graph depicting reporter cell luciferase activity versus time when seeded
onto irradiated melanoma cells with luminescence images on day 13. (c, d) Graph depicting reporter cell luciferase activity versus time when seeded onto
vemurafenib (Vem)-treated melanoma cells with luminescence images on day 13. (e, f) Graph depicting reporter cell luciferase activity versus time when seeded
onto irradiated melanoma cells in transwell plates with luminescence images on day 11. Error bars are mean±SEM, n¼ 3; *Po0.05 one-way analysis of
variance (ANOVA) test.
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breast cancer cells (Huang et al., 2011), we sought to deter-
mine whether there is a role for PGE2 in a caspase 3–mediated
mechanism of melanoma tumor repopulation. We measured
PGE2 production induced by irradiation of melanoma cells in
the supernatant of cells and found that PGE2 levels are increa-
sed after radiation of melanoma cells (Figure 5a and b).
In comparison with the supernatant of irradiated wild-type
A375 cells, PGE2 levels were significantly lower in irradiated
A375 caspase 3 shRNA cells (Figure 5a) or after treatment with
indomethacin (a cyclooxygenase I and II inhibitor that should
significantly reduce PGE2 production) (Figure 5b). Further-
more, treatment of irradiated A375 cells with 100mM
indomethacin in a transwell plate decreased the growth-
stimulating effect of dying melanoma cells on living mela-
noma cells by 432-fold (Figure 5c). Finally, we also obtained
evidence that PGE2 was induced by radiation in A2508
cells and its production was decreased with indomethacin
(Supplementary Figure S5a online). The importance of PGE2
was again demonstrated by the fact that indomethacin
significantly reduced cell death–stimulated A2508Fluc repo-
pulation (Supplementary Figure S5b online). Therefore, we
conclude that PGE2 secretion is crucial to caspase 3–mediated
dying melanoma cell stimulation of living cell growth.
DISCUSSION
Our results illustrate that dying cells promote the growth of
living melanoma tumor cells after cytotoxic treatment via a
caspase 3–mediated mechanism. Given that conventional
cancer studies often target the enhancement of apoptosis in
treatment, this report presents data that suggest a very
counterintuitive idea in cancer cell biology. In our study, we
confirmed that radiation and vemurafenib activated caspase 3
in melanoma cells. Importantly, we demonstrated that dying
melanoma cells treated with radiation or vemurafenib stimu-
late the growth of living tumor cells in vitro and in vivo.
Furthermore, when we attenuated the activities of caspase 3
with caspase 3 shRNA, a caspase 3 dominant-negative gene,
or with genetic deletion of caspase 3 in MEF cells, the growth
stimulation of irradiated, dying cells on living cells was
substantially decreased. Therefore, we propose a role for the
‘‘Phoenix Rising’’ pathway in melanoma tumor repopulation
that to our knowledge is previously unreported. In this path-
way, dying melanoma cells activate caspase 3 that results in
the ultimate effect of increased surviving tumor cell growth
through a mechanism involving secretion of growth-stimulat-
ing factors such as PGE2.
The current literature contains several examples of caspases
acting in pathways other than apoptosis. For instance, cas-
pases are involved in cell differentiation (Kang et al., 2004;
Szymczyk et al., 2006; Fujita et al., 2008), dedifferentiation of
fibroblasts into pluripotent stem cells (Li et al., 2010a), and
osteoclast differentiation (Szymczyk et al., 2006). Caspases
may activate T cells that could further influence tumor biology
through inflammatory factors and immune evasion (Kennedy
et al., 1999). In melanoma, basal caspase 3 expression
correlates with invasion of melanoma cells (Liu et al., 2013).
Essentially, the involvement of caspase 3 in melanoma tumor
repopulation is consistent with the established multifunctional
nature of caspases.
Overall, we propose a counterintuitive strategy to inhibit
caspase 3 for therapeutic gain in melanoma treatment. On the
basis of our results, the combination of radiation with a topical
caspase 3 inhibitor could serve as a localized treatment for
superficial melanomas. For metastatic tumors, combining
caspase 3 inhibitors with radiation and/or vemurafenib treat-
ment may also be beneficial. Interestingly, caspase 3 knockout
mice have a normal lifespan and only have issues with female
fertility (Matikainen et al., 2001) and with eye and ear
development (Kuida et al., 1996; Makishima et al., 2011).
Currently, pan caspase inhibitor drugs are in clinical trials for
hepatitis C, nonalcoholic steatohepatitis, and liver reperfusion
injury with promising results (Baskin-Bey et al., 2007;
Shiffman et al., 2010; Ratziu et al., 2012). In essence, we
believe that our finding of a caspase 3–mediated mechanism
of melanoma tumor repopulation after cytotoxic therapy
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Figure 3. Cell death–stimulated growth of A375Fluc melanoma cells in vivo.
A small number (1 104) of A375Fluc cells were injected with a larger number
(2 105) of feeder cells treated with 10 Gy radiation or vemurafenib 20mM in
the right leg or untreated feeder cells on the left leg. (a) Graph presenting fold
difference in A375Fluc luciferase activity and (b) luminescence images of
10 Gy-irradiated feeder cells (right leg) compared with untreated feeder cells
(left leg). (c) Graph presenting fold difference in A375Fluc luciferase activity
and (d) luminescence images of feeder cells treated with vemurafenib 20mM
(right leg) compared with untreated feeder cells (left leg). Error bars are
mean±SEM, n¼4 radiation, n¼ 5 vemurafenib; *Po0.05, t-test.
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suggests a major rethinking of our understanding of melanoma
and cancer biology that could potentially improve our limited
available treatments for patients with melanoma.
MATERIALS AND METHODS
Cell lines, drugs, and irradiation
A375 melanoma cells and MEF cells were obtained from American
Type Tissue Culture (Manassas, VA). A2508 melanoma cells were
provided by Dr Jennifer Zhang from Duke University (Durham, NC).
DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum was used to culture the cells at 37 1C under 5% CO2
and 95% air. Vemurafenib was purchased from Selleck Chemicals
(Houston, TX) and indomethacin was purchased from Sigma-Aldrich
(St Louis, MO). Drugs were dissolved in DMSO and diluted with
culture medium. Cells were irradiated using the X-Rad320 X-ray
machine at Duke University Medical Center (Durham, NC). The dose
rate was 4.50 cGy s 1.
Gene transduction into A375 cells
The lentiviral vector pLEX system was purchased from Open
Biosystems (Huntsville, AL) and used to introduce genes into A375
and A2508 cells. The firefly luciferase gene (Fluc) was obtained from
Promega (Madison, WI) and transferred from the plasmid pGL4.31-
luc2 into A375 and A2508 cells to create luciferase-labeled A375
(A375Fluc) and A2508 (A2508Fluc) cells, respectively. The activated
caspase 3 reporter gene was cloned into the lentiviral vector pLEX.
For shRNA against human caspase 3, two shRNA-encoding lentivirus
vectors in the GIPZ backbone were purchased from Open Biosystems
(now Thermo-Fisher): clone 1: V2LHS_15044 and clone 2:
V2LHS_15045. For caspase 3 dominant-negative A375 and A2508
cells, we mutated a key cysteine in the catalytic domain of murine
caspase 3 (C163-A) through site-directed mutagenesis. All the
lentiviral vectors were packaged into live lentiviral viruses in
293T cells following the manufacturer’s instructions. Target A375
and A2508 cells were infected with the lentivirus vector and
polybrene in culture medium. Transfected cells were selected for
with puromycin 1mg ml 1 in culture medium. All lentivirus vectors
were made according to the manufacturer’s instructions.
Bioluminescence and fluorescence imaging
To measure luciferase activity in vitro, we used the Synergy
H1 Hybrid Multi-Mode Microplate Reader (BioTek, Winooski, VT).
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D-luciferin (0.06 mg per well) from Promega was added to wells.
To image luciferase activity in vitro and in vivo, the IVIS Kinetic
instrument from Caliper Life Sciences (Optical Molecular Imaging
and Analysis, Durham, NC) was used. Mice were injected with
150 mg kg 1 body weight of D-luciferin intraperitoneally in 100ml of
deionized water and then anesthetized with continuous 2.5%
isoflurane. Imaging was carried out within 10 minutes after adminis-
tration of D-luciferin. For fluorescence imaging of GFP-expressing
cells, the Zeiss AX10 microscope (Carl Zeiss Microscopy,
Thornwood, NY) was used.
Activated caspase 3 reporter experiments
A375 cells transduced with the caspase 3 reporter gene were seeded
(1 105 cells per well) into 6-well plates and treated with vehicle,
10 Gy radiation, or vemurafenib 20mM for 1, 3, and 5 days. Luciferase
activity was measured at three time points and cells were counted
using the Bio-Rad cell counter (Hercules, CA) by Trypan blue
exclusion to calculate a luciferase activity per cell ratio. GFP images
were taken on day 5.
Tumor cell growth in vitro and in vivo
In vitro, 200–500 untreated A375Fluc or A2508Fluc cells were
seeded onto a larger number (1 105) of A375 or A2508 feeder cells
within 24 hours after treatment in either 12- or 24-well plates,
or in 12- or 24-well transwell plates in 2% fetal bovine serum
culture medium. Feeder cells were either untreated or lethally
treated with 10 Gy radiation or with vemurafenib 20 or 30mM
for 3 days. Luciferase activity was monitored every 2–3 days
over a 2-week period with IVIS Kinetic images taken at the end of
2 weeks.
Male nude mice between 6 and 8 weeks of age were purchased
from Jackson Laboratory (Bar Harbor, ME). Xenograft injections
contained a small number (1 104) of A375Fluc cells mixed with a
larger number (2 105) of A375 feeder cells (lethally treated with
10 Gy radiation or vemurafenib 20mM for 3 days in the right leg or
untreated in the left leg). Cells were resuspended in phosphate-
buffered saline and 50ml was injected subcutaneously into the hind
legs of the nude mice. Bioluminescence was measured three times
over 2 weeks. Once tumors became visible, tumor volume was
measured and bioluminescence was normalized to the tumor volume.
All animal experiments were approved by the Institutional Animal
Care and Use Committee of the Duke University.
ELISA assay for PGE2 concentration
A375 or A375 C3 shRNA cells were either untreated or irradiated
with 10 Gy and plated in 12-well plates (1 105 cells per well) in
2% fetal bovine serum culture medium. Supernatant from the
cells was collected 72 hours after radiation and diluted 50-fold. Cells
were counted using Trypan blue exclusion using the Bio-Rad cell
counter in order to normalize PGE2 concentration to cell number.
PGE2 was measured in the supernatant following a protocol
from an ELISA kit purchased from Cayman Chemical Company
(Ann Arbor, MI).
Western blot analysis
For running gel electrophoresis, 40mg of protein per sample was
loaded on a 10% polyacrylamide gel. Gels were transferred to
a polyvinylidene difluoride membrane to be blotted with antibodies
for cleaved caspase 3 (rabbit) and b-actin (mouse).
Statistical analysis
One-way analysis of variance tests and Student’s two-tailed t-tests
were used to analyze the experiment results. A P-value of 0.05 was
considered statistically significant.
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Figure 5. Caspase 3 regulates radiation-induced prostaglandin E2 (PGE2)
secretion and indomethacin (Indo) decreases dying melanoma cell–stimulated
living cell growth. Melanoma cells were irradiated and PGE2 concentrations
were measured in the supernatant using an ELISA assay for PGE2 72 hours after
radiation. (a) Graph showing PGE2 concentration per cell number in irradiated
or untreated A375 and A375 C3shRNA cells. (b) Graph showing PGE2
concentration per cell in irradiated or untreated A375 cells treated with
indomethacin 25 or 50mM. (c) Graph showing reporter luciferase activity versus
time when seeded onto irradiated A375 cells treated with indomethacin 25,
50, or 100mM with luminescence images on day 10. Error bars are
mean±SEM, n¼3. *Po0.05, one-way analysis of variance (ANOVA) test.
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